Amgen is trading 4.2% up now at $406.39 after reporting better-than-expected second-quarter results and raising its 2026 outlook.
- Revenue grew 10% year-over-year to approximately $10.1 billion, with EPS exceeding estimates driven by 9% product sales growth and strong volume across key drugs.
- Management raised full-year revenue and EPS guidance, signaling confidence in its high-growth portfolio.
- The broader biotech sector and equity markets are also trending higher, providing additional support for the stock.